Evolus, Inc. (EOLS)
NASDAQ: EOLS · Real-Time Price · USD
6.85
+0.04 (0.59%)
At close: Dec 5, 2025, 4:00 PM EST
6.81
-0.04 (-0.58%)
After-hours: Dec 5, 2025, 5:41 PM EST
Company Description
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia.
It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels.
The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Feb 8, 2018 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 332 |
| CEO | David Moatazedi |
Contact Details
Address: 520 Newport Center Drive, Suite 1200 Newport Beach, California 92660 United States | |
| Phone | 949 284 4555 |
| Website | evolus.com |
Stock Details
| Ticker Symbol | EOLS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001570562 |
| CUSIP Number | 30052C107 |
| ISIN Number | US30052C1071 |
| Employer ID | 46-1385614 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David Moatazedi | President, Chief Executive Officer and Director |
| Tomoko Yamagishi-Dressler | Chief Marketing Officer |
| Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of Research and Development |
| Tatjana Mitchell | Chief Financial Officer |
| Nareg Sagherian | Head of Global Investor Relations and Corporate Communications |
| Jeffrey J. Plumer | General Counsel |
| Kurt Knab | Senior Vice President of Sales |
| Jessica Novak | Senior Vice President of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 5, 2025 | 10-Q | Quarterly Report |
| Nov 5, 2025 | 8-K | Current Report |
| Sep 8, 2025 | 8-K | Current Report |
| Aug 18, 2025 | SCHEDULE 13G | Filing |
| Aug 14, 2025 | SCHEDULE 13G/A | Filing |
| Aug 14, 2025 | SCHEDULE 13G | Filing |
| Aug 5, 2025 | 10-Q | Quarterly Report |